AI, automation & earnings fuel market buzz

*together with Option Pit

Good day, 360!

Here are some of our top movers today. If you missed the inside scoop on the Game Plan yesterday, no worries we’ve got it HERE. If you Be the best prepared trader on the Street!

FOCUS LIST🔎

VOR - Up over 130% in the pre-market after announcing global license agreement for autoimmune asset Telitacicept, securing $125M payment and $175M private placement 

CYN - Up over 65% in pre after announcing next-generation robotics, automation and AI technologies at Automatica in collaboration with NVIDIA  

KEQU - Up over 18% in pre after reporting better than expected earnings

HOTLIST🔥

VOR - Up over 130% in the pre-market after announcing global license agreement for autoimmune asset Telitacicept, securing $125M payment and $175M private placement 

Vor Biopharma Inc. (VOR) operates as a clinical-stage cell and genome engineering company.

In the after-hours yesterday, the company announced a global license agreement for autoimmune asset Telitacicept, securing $125M payment and $175M private placement.

Highlights include:

-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis

-RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties

Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.

Shares of VOR traded up over 130% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $1.47. Beyond that, $1.60, $1.80, $2 and $2.20 come into play.

Below $1.47, targets to the downside are $1.20, $1.10, $1, $0.80 and then a gap fill at $0.5544.

CYN - Up over 65% in pre after announcing next-generation robotics, automation and AI technologies at Automatica in collaboration with NVIDIA 

Cyngn Inc. (CYN) is an autonomous vehicle (AV) technology company that develops autonomous driving software in the United States.

In the pre-market this morning, the company announced its collaboration with NVIDIA as part of the Automatica 2025 robotics and automation showcase. The collaboration highlights how Cyngn is leveraging the NVIDIA Isaac robotics platform to power next-generation autonomous vehicle solutions for industrial applications.

As featured in NVIDIA's recent blog post, Cyngn was selected among a handful of robotics innovators using NVIDIA Isaac technologies to accelerate safe, scalable autonomy across dynamic, real-world environments. Automatica 2025, the world's leading trade fair for smart automation and robotics, provides a global stage for demonstrating how AI-powered solutions are transforming manufacturing and logistics.

Shares of CYN traded up over 65% in the pre-market in reaction to the announcement.

The first target for bulls is the pre-market high at $11.97. Beyond that, $13, $15 and $17.85.

Below $11.97, targets to the downside are $10.20, $9.30, $8.20, $7.80, $6.30 and then a gap fill at $5.01.

KEQU - Up over 18% in pre after reporting better than expected earnings 

Kewaunee Scientific Corporation (KEQU) designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products.

In the after-hours yesterday, the company announced results for its fourth quarter and its fiscal year ended April 30, 2025.

Highlights include:

Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. 

Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter.

 Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prior year quarter. 

Diluted earnings per share were $1.63 compared to diluted earnings per share of $3.71 in the prior year quarter. EBITDA1 for the quarter was $9,671,000 compared to $2,265,000 for the prior year quarter.

The Company's order backlog was $214.6 million on April 30, 2025, a slight decrease from $221.6 million on January 31, 2025, and an increase from $155.6 million on April 30, 2024.

Shares of KEQU traded up over 18% in reaction to the financial results.

The first target for bulls is the pre-market high at $50. Beyond that, $52, $53, $54, $55 and $56.50 come into play.

Below $50, targets to the downside are $47, $45, $43 and then a gap fill at $40.48.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed past the MOON 🌝.  Simply text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.